该行表示，折扣持续的线上渠道可能第三季增长超过线下零售渠道，导致渠道组合的折扣力度更大。尽 管如此，改行认为负面影响正在减弱，因为线下零售折扣同比变化幅度有所缩小。该行预计，2026财年 下半年，费用控制措施将持续缓解毛利率压力。目前预计，2026财年下半年度收入将下降10.8%，净利 将增12%至4.59亿元人民币，这意味着2026财年净利润将同比减3%。 该行表示，公司2026财年第三财季销售额下降符合管理层预期，和第二季相当，该行相信线下门店客流 量依然受压，12月需求疲弱持续。其主要品牌耐克表示，中国的重置需要时间，滔搏和耐克紧密合作构 建长期增长基础。该行相信这将转变为对滔搏的持续支持，形式包括:批发折扣及库存回购。 麦格理发布研报称，下调滔搏(06110)目标价5%至3.9港元，评级"跑赢大市"。该行下调对滔搏2026财年 纯利预测4.2%，下调2027财年预测3.9%，主要是需求疲软之下收入预测降低，导致支出比例升高。 ...

智通财经APP获悉，麦格理发布研报称，下调滔搏(06110)目标价5%至3.9港元，评级"跑赢大市"。该行 下调对滔搏2026财年纯利预测4.2%，下调2027财年预测3.9%，主要是需求疲软之下收入预测降低，导 致支出比例升高。 该行表示，折扣持续的线上渠道可能第三季增长超过线下零售渠道，导致渠道组合的折扣力度更大。尽 管如此，改行认为负面影响正在减弱，因为线下零售折扣同比变化幅度有所缩小。该行预计，2026财年 下半年，费用控制措施将持续缓解毛利率压力。目前预计，2026财年下半年度收入将下降10.8%，净利 将增12%至4.59亿元人民币，这意味着2026财年净利润将同比减3%。 该行表示，公司2026财年第三财季销售额下降符合管理层预期，和第二季相当，该行相信线下门店客流 量依然受压，12月需求疲弱持续。其主要品牌耐克表示，中国的重置需要时间，滔搏和耐克紧密合作构 建长期增长基础。该行相信这将转变为对滔搏的持续支持，形式包括:批发折扣及库存回购。 ...

Core Viewpoint - Ctrip Group reported strong financial performance in Q3 2025, with a significant increase in revenue and net profit, primarily driven by substantial other income from the sale of a stake in MakeMyTrip [2][5]. Financial Performance - In the first three quarters of 2025, Ctrip's revenue reached 471 billion, a year-on-year increase of 15.9%, and net profit was 291 billion, up 93.6% [2]. - The Q3 net profit was 199 billion, surpassing Kweichow Moutai's net profit of 192 billion by 3.6% [2]. - Ctrip's revenue in 2023 doubled to 446 billion, with a revenue index of 125, and is projected to reach 534 billion in 2024 [5]. - From 2019 to Q3 2025, Ctrip's revenue had a compound annual growth rate of 9.5% [7]. Revenue Breakdown - Accommodation bookings and transportation ticketing are the two main revenue streams, contributing 80% of total income [8]. - In 2019, accommodation revenue was 140 billion and transportation revenue was 135 billion, together accounting for 77% of total revenue [9]. - In 2023, accommodation and transportation revenue indices reached 128 and 132, respectively, indicating a strong recovery post-pandemic [10]. Cost Management - Ctrip has significantly improved its cost management, reducing total expense ratio by 12 percentage points since 2019 [14]. - In 2023, the gross profit margin increased to 81.8%, while the total expense ratio decreased to 56.3% compared to 2019 [16]. - By Q3 2025, Ctrip achieved a gross profit of 381 billion with a gross profit margin of 81.1% [16]. Competitive Landscape - The travel market is expected to see over 6 billion domestic trips and a total spending of 6.5 trillion by 2025, indicating a competitive environment with numerous players [22]. - Ctrip faces competition from various OTA platforms, traditional travel agencies, and new entrants like JD.com and Meituan [23][24]. - Ctrip's unique advantages include a vast hotel resource network, with over 1.4 million global hotel partnerships and nearly 100% coverage of high-star hotels in China [28]. Strategic Advantages - Ctrip has established a strong market position by acquiring competitors and enhancing its service offerings [25]. - The company operates over 7,000 offline stores across more than 300 cities, providing a significant advantage in customer trust and service [31]. - Ctrip's call center, with approximately 12,000 seats, offers 24/7 support, enhancing customer satisfaction and loyalty [32].

Investment Rating - The report maintains a "Buy" investment rating for the company [1] Core Insights - The company's performance has stabilized at the bottom, with successful channel expansion [1] - The company reported a total revenue of 760 million yuan for the first three quarters of 2025, a decrease of 36% year-on-year, and a net loss attributable to shareholders of 10 million yuan, a decrease of 117% year-on-year [4][5] - The company has shown significant improvement in cost control, with a gross margin decrease of 3 percentage points to 61.22% and a sales expense ratio decrease of 31 percentage points to 34.98% [5] - The company has successfully opened new channels, particularly in banquet scenarios, with a notable increase in events in Hunan province [6] Summary by Sections Financial Performance - For Q3 2025, total revenue was 198 million yuan, an increase of 1% year-on-year, with a net loss of 19 million yuan compared to a loss of 65 million yuan in Q3 2024 [4] - The company’s contract liabilities decreased by 43% to 117 million yuan [5] Investment Highlights - The company is actively adjusting its business strategy, focusing on cost control and enhancing its product offerings, which are gaining market recognition [7] - Earnings per share (EPS) forecasts for 2025-2027 are 0.04, 0.24, and 0.49 yuan respectively, with corresponding price-to-earnings (PE) ratios of 1461, 279, and 135 times [7] Market Strategy - The company is deepening its marketing strategies through banquet and consumer engagement, leading to improved sales performance [6] - New product launches, such as the co-branded product "Jiu Gui · Free Love," have quickly gained consumer acceptance [6]

Performance Review - The company's revenue for the first three quarters of 2025 reached 1.16 billion, a year-on-year increase of 4.0%, with net profit attributable to shareholders at 100 million, up 408% year-on-year [1] - In Q3 2025, revenue was 370 million, representing an 11.2% year-on-year growth, and net profit turned positive at 30 million compared to a loss of 10 million in Q3 2024 [1] - The increase in performance is attributed to strong gross margin and investment income, with single-store revenue growth of 30.8% year-on-year [1] Product Structure and Cost Control - The company's gross margin improved by 4.1 percentage points to 69.0% in Q3 2025, driven by product structure optimization [2] - Selling and administrative expense ratios decreased by 4.0 percentage points and 0.7 percentage points to 51.5% and 9.6%, respectively, due to operational efficiency improvements [2] - Operating cash flow showed a net outflow of 50 million in Q3 2025, primarily due to increased procurement and payments related to gold leasing [2] Development Trends - The company plans to continue enhancing and upgrading its channels, focusing on brand strength in core cities and expanding into high-potential commercial spaces in lower-tier cities [3] Profit Forecast and Valuation - The earnings per share (EPS) forecast for 2025 and 2026 has been raised by 27% and 38% to 0.35 and 0.44, respectively, with the current stock price corresponding to 8.4 and 7.9 times the 2025 and 2026 P/S ratios [4] - The target price is set at 40.78, implying a 25% upside potential based on 10.5 and 10.0 times the 2025 and 2026 P/S ratios [4]

Core Insights - The company reported a revenue of 11.116 billion yuan in Q3 2025, a year-over-year decrease of 1.74%, and a net profit attributable to shareholders of 194 million yuan, down 6.58% year-over-year [1] - For the first three quarters of 2025, the company achieved a revenue of 33.807 billion yuan, an increase of 1.89% year-over-year, and a net profit attributable to shareholders of 1.007 billion yuan, up 57.02% year-over-year [1] Financial Performance - In Q3 2025, the company's gross margin was 5.71%, a decrease of 0.17 percentage points year-over-year [1] - The expense ratios for sales, management, and R&D were 1.09%, 1.89%, and 0.14% respectively, with year-over-year changes of -0.13, -0.35, and +0.04 percentage points [1] - The net profit margin for Q3 2025 was 1.74%, down 0.09 percentage points year-over-year [1] Year-to-Date Performance - For the first three quarters of 2025, the gross margin was 5.46%, a decrease of 0.27 percentage points year-over-year [1] - The expense ratios for sales, management, and R&D were 1.07%, 1.83%, and 0.08% respectively, with year-over-year changes of -0.15, -0.27, and -0.01 percentage points [1] - The net profit margin for the first three quarters of 2025 was 2.98%, an increase of 1.05 percentage points year-over-year [1] Investment Outlook - The company is expected to achieve net profits attributable to shareholders of 1.163 billion yuan, 993 million yuan, and 1.124 billion yuan for the years 2025, 2026, and 2027 respectively [2] - The current market capitalization corresponds to a price-to-earnings ratio of 9X, 11X, and 9X for the years 2025, 2026, and 2027 [2] - The investment rating is maintained at "Accumulate" [2]

Summary of Hengan International Conference Call Company Overview - **Company**: Hengan International - **Industry**: Consumer Goods, specifically in hygiene products such as tissue paper and sanitary products Key Points and Arguments Sales and Profit Outlook - Hengan International expects sales and profits for 2025 to remain flat compared to 2024, with a 2-3% decline in the first half of the year but anticipates improvement in the second half to stabilize annual performance [2][5] - The company maintains a strong cash flow, with an annual dividend of CNY 1.4 per share [2][5] Product Segments Performance - **Tissue Paper Segment**: - The average selling price (ASP) has shown a turning point, with expectations of at least a 3% growth in the second half of the year [2][6] - Gross margin is expected to improve due to controlled promotional expenses and a favorable product mix, including high-end products [2][6][4] - **Sanitary Products Segment**: - The sanitary napkin market is highly competitive, particularly online, with domestic brands aggressively competing for market share [2][8] - Hengan's sanitary napkin sales saw a 14% decline in the first half, but improvements are expected in the second half, potentially reducing the annual decline to around 10% [3][4] - The company plans to enhance penetration in traditional small stores and explore new retail models like instant retail and community group buying [2][10] Market Dynamics - The competition in the sanitary napkin market remains intense, especially from online brands [8][9] - Hengan's offline sales account for approximately 51% of its sanitary napkin sales, with a strong presence in lower-tier cities [10][11] - The company aims to balance online and offline sales, with online sales expected to approach 30% [9][10] Cost and Margin Considerations - Wood pulp costs are under pressure, but the impact on gross margins is expected to be limited due to stable pricing and inventory management [7][15] - The overall expense ratio is projected to remain around 22%, consistent with the first half of the year [4][13] Capacity and Production Plans - Hengan's current production capacity is approximately 1.4 million tons, with plans to increase it to nearly 1.8 million tons by 2026 through new projects in Guangdong, Xiaogan, and Chongqing [3][16] - The company operates at a capacity utilization rate of over 80% [16] Future Growth Expectations - The tissue paper market is expected to grow at a mid-single-digit rate due to low penetration [14] - The sanitary products market faces challenges but may benefit from improved quality standards and the exit of foreign brands [14] Dividend Policy - The dividend policy remains stable, with a payout of CNY 1.4 per share, consistent with previous years [19] Strategic Focus - Hengan International is focused on expanding its market share amidst competitive pressures, particularly in the tissue paper segment where the overall market share of the top four brands is below 30% [16] Additional Important Insights - The company has no immediate plans for significant capital expenditure increases, maintaining a budget of around CNY 1 billion annually [17][18] - The overall market environment is being closely monitored to adapt strategies in response to competitive dynamics [8][9]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - In the first half of 2025, the company achieved a revenue of 9.01 billion, a year-on-year decline of 3.8%, while the net profit attributable to shareholders was 180 million, a year-on-year increase of 7.8%. In Q2 alone, the revenue was 4.07 billion, down 2.6% year-on-year, but the net profit attributable to shareholders surged by 82.6% to 40 million, with a non-recurring net profit growth of 120.5% to 40 million [2][4]. Summary by Sections Financial Performance - The company reported a total revenue of 90.1 billion for the first half of 2025, down 3.8% year-on-year, with a net profit of 1.8 billion, up 7.8%. In Q2, revenue was 40.7 billion, down 2.6%, while net profit reached 0.4 billion, up 82.6%, and non-recurring net profit increased by 120.5% to 0.4 billion [2][4]. Operational Adjustments - The company optimized its store layout by closing 16 stores, resulting in a total of 1,084 stores, while opening 29 new stores and closing 45. The revenue from comprehensive supermarkets and community fresh supermarkets saw a limited decline of 2% and 4% respectively, while rural supermarkets experienced a 12% drop. The company completed upgrades on 30 stores, enhancing shopping environments and product quality [9]. Supply Chain and Cost Management - The company focused on streamlining expenses, reducing four types of period costs by 73.76 million. The logistics costs decreased by 6.16% year-on-year, and the satisfaction rate of logistics to stores improved by 6%. The company is also advancing the construction of a logistics base in Hohhot and a modern bakery factory [9]. Future Outlook - The company aims to strengthen its core categories such as fresh and processed fresh products while expanding its supply chain coverage. The expected EPS for 2025-2027 is projected to be 0.31, 0.38, and 0.45 respectively, maintaining a "Buy" rating [9].

Core Viewpoint - The company reported a net profit of 75.26 million yuan for 1H25, exceeding expectations due to effective cost control and a low profit base from the previous year [1] Revenue and Profit Analysis - Total revenue for 1H25 was 1.015 billion yuan, a year-on-year decrease of 4.22%, while net profit increased by 29.58% [1] - Online channel revenue was 632 million yuan, down 1.3% year-on-year, while offline channel revenue was 382 million yuan, down 8.8% [1] - The core product, bird's nest porridge, saw sales of 43.82 million yuan, reflecting a growth of 6.3% year-on-year [1] Cost and Margin Insights - The company achieved a slight increase in gross margin by 3.5 percentage points, with a reduction in sales expense ratio by 1.6 percentage points [1] - The tax rate increased from 23.0% to 29.6% year-on-year, influenced by profit growth and sales expense tax deductions [1] Future Outlook - The company is actively adjusting its offline business and maintaining a strong online presence, which is expected to benefit from a potential recovery in macro consumption [1] - Long-term strategies focus on consolidating competitive advantages through multiple channels for sustainable growth [1] Earnings Forecast and Valuation - The earnings forecast for 2025 and 2026 has been adjusted downwards by 3.0% and 7.8% to 168 million yuan and 192 million yuan respectively [2] - The target price remains at 7.7 HKD, with the current stock price corresponding to a P/E ratio of 19.7 for 2025 and 17.0 for 2026 [2]

Core Viewpoint - The report from Dongfang Securities indicates that Huayuan Bio achieved a net profit attributable to shareholders of 162 million yuan in the first half of the year, representing a year-on-year increase of 13.67%, with a non-recurring net profit of 150 million yuan, up 37.36% year-on-year, primarily due to effective cost control [1] Financial Performance - The company's performance is closely linked to vitamin prices, which saw a rapid increase starting from the second half of last year, although there was a slight decline in vitamin prices in the latter half of 2025 [1] - Despite the stable growth in revenue expected for the year, the profit performance remains promising due to cost control and business structure [1] Strategic Development - The "one vertical and one horizontal" strategy is showing positive effects, indicating a favorable long-term development outlook for the company [1] - The company is the only global producer with a full industrial chain for VD3, holding a 70% market share in NF-grade cholesterol, the only legal raw material for VD3 production [1] Cost and Margin Analysis - In the context of declining VD3 prices, the company maintains a cost advantage, with a gross margin of 62.99% for vitamin products in the first half of 2025, an increase of 8.12 percentage points year-on-year [1] Production Capacity and Future Projects - The annual production project for 6,000 tons of VA powder has been completed, while projects for 5,000 tons of VB6 and 200 tons of biotin are in trial production preparation [1] - Other vitamin products are expected to contribute to performance growth in the near future [1] Drug Development Pipeline - The company currently has seven products under review and five in research, with the potential to re-enter an upward trajectory following the elimination of the impact from centralized procurement [1] Valuation - Based on comparable companies, a target price of 18.90 yuan is set for the company, corresponding to a 30 times price-to-earnings ratio for 2025, maintaining a "buy" rating [1]